
Tachyon Therapeutics: Innovating cancer treatment through selective compounds and advanced clinical research.
Tachyon Therapeutics, founded with a mission to innovate cancer treatment, focuses on developing novel, selective compounds to improve patient outcomes. The company's vision is to accelerate the development of first-in-class therapeutics targeting significant new drug targets in oncology. Tachyon's flagship product, TACH101, is currently in Phase 1 clinical trials to evaluate its safety, pharmacokinetics, and anti-tumor activity in patients with advanced cancer.
Notable figures affiliated with Tachyon Therapeutics include a distinguished management team and a board of directors with extensive experience in biotechnology and pharmaceuticals. The company has garnered attention from prominent investors in the healthcare sector. Key achievements include the initiation of multicenter Phase 1 clinical studies for TACH101, demonstrating their commitment to advancing cancer treatment. Tachyon Therapeutics' innovative approach has the potential to significantly impact the oncology field by providing new, effective treatment options for cancer patients.

Tactiva Therapeutics

PanTher Therapeutics
panthertx.com

Palm Therapeutics

Treadwell Therapeutics
treadwelltx.com

Checkpoint Therapeutics
checkpointtx.com

OncoSpherix
oncospherix.com

Onchilles Pharma

Parthenon Therapeutics
parthenontx.com

OnCusp Therapeutics
oncusptx.com

Telo Therapeutics

Camino Pharma
caminopharma.com

Tychon Bioscience
tychonbio.com

Window Therapeutics
windowtx.com

Tau Therapeutics

Ostentus Therapeutics
Companies similar to Tachyon Therapeutics include Tactiva Therapeutics, PanTher Therapeutics, Palm Therapeutics and Treadwell Therapeutics.
Tachyon Therapeutics was founded in 2019.
Tachyon Therapeutics' headquarters is located in San Francisco, CA, US.
Tachyon Therapeutics' most recent funding round was for $7.1M (USD) in March 2023.
As of Mar 1, 2023, Tachyon Therapeutics has raised a total of $18.7M (USD).
Tachyon Therapeutics has 5 employees as of Feb 4, 2024.